|Bid||333.70 x N/A|
|Ask||368.80 x N/A|
|Day's range||349.00 - 353.00|
|52-week range||229.00 - 405.10|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.